20:31 , Sep 14, 2018 |  BC Week In Review  |  Company News

Acorda loses Amprya appeal, reports Inbrija PDUFA delay

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $10.30 (37%) to $17.25 the week of Sept. 10 following setbacks related to multiple sclerosis drug Ampyra dalfampridine and Parkinson's disease candidate Inbrija levodopa inhalation powder (CVT-301). On Sept. 10,...
20:29 , Sep 10, 2018 |  BC Extra  |  Company News

Acorda loses appeal to shield Ampyra from generic entry

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $6.75 (25%) to $20.80 Monday after the U.S. Court of Appeals for the Federal Circuit upheld a 2017 district court ruling that leaves multiple sclerosis drug Ampyra dalfampridine with no...
22:04 , Aug 14, 2018 |  BC Extra  |  Company News

Management tracks: Cheng departing Gilead as CMO

Gilead Sciences Inc. (NASDAQ:GILD) said CMO Andrew Cheng will leave the company, effective Sept. 7, after five months in the role to pursue another opportunity. Gilead did not say who would replace Cheng, who joined...
06:20 , Aug 10, 2018 |  BC Week In Review  |  Company News

Acorda, Mylan reach settlement for Ampyra generic

Acorda Therapeutics Inc. (NASDAQ:ACOR) reached a conditional settlement with Mylan N.V. (NASDAQ:MYL) that would allow Mylan to market a generic version of multiple sclerosis drug Ampyra dalfampridine in the U.S. in 2025 or earlier under...
23:03 , Aug 6, 2018 |  BC Extra  |  Company News

Acorda, Mylan reach settlement for Ampyra generic

Acorda Therapeutics Inc. (NASDAQ:ACOR) reached a conditional settlement with Mylan N.V. (NASDAQ:MYL) that would allow Mylan to market a generic version of multiple sclerosis drug Ampyra dalfampridine in the U.S. in 2025 or earlier under...
20:06 , Jul 27, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck...
18:27 , Jul 27, 2018 |  BC Week In Review  |  Company News

Court of Appeals denies Acorda's injunction for Ampyra

Acorda Therapeutics Inc. (NASDAQ:ACOR) said the U.S. Court of Appeals for the Federal Circuit denied the company's injunction to prevent generic competition for Ampyra dalfampridine from entering the market while an appeal of a district...
22:36 , Jul 25, 2018 |  BC Extra  |  Company News

Court of Appeals denies Acorda's injunction for Ampyra

Acorda Therapeutics Inc. (NASDAQ:ACOR) lost $4.15 (14%) to $24.55 on Wednesday after the U.S. Court of Appeals for the Federal Circuit denied the company's injunction to prevent generic competition for Ampyra dalfampridine from entering the...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
16:20 , Jun 15, 2018 |  BC Week In Review  |  Company News

Acorda gains following Ampyra appeal arguments

Acorda Therapeutics Inc. (NASDAQ:ACOR) added over $117 million in market cap on June 8 following oral arguments held June 7 in its appeal of a district court ruling invalidating four of five patents for multiple...